Electromed, Inc. (NYSE:ELMD) Director Andrew Summers Sells 50,751 Shares

Electromed, Inc. (NYSE:ELMD) Director Andrew Summers sold 50,751 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.30, for a total value of $1,385,502.30. Following the sale, the director now directly owns 65,714 shares of the company’s stock, valued at approximately $1,793,992.20. This trade represents a 43.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Andrew Summers also recently made the following trade(s):

• On Thursday, February 20th, Andrew Summers sold 35,273 shares of Electromed stock. The stock was sold at an average price of $28.83, for a total transaction of $1,016,920.59.
• On Wednesday, December 4th, Andrew Summers sold 12,731 shares of Electromed stock. The shares were sold at an average price of $29.98, for a total transaction of $381,675.38.
• On Monday, December 2nd, Andrew Summers sold 17,463 shares of Electromed stock. The shares were sold at an average price of $30.09, for a total transaction of $525,461.67.

Electromed Trading Down 3.6 %

Shares of Electromed stock opened at $26.97 on Tuesday. Electromed, Inc. has a 12-month low of $13.74 and a 12-month high of $35.56. The company has a market cap of $230.78 million, a P/E ratio of 35.96 and a beta of 0.33. The company’s fifty day simple moving average is $31.37 and its two-hundred day simple moving average is $25.49.

Analyst Ratings Changes

Several analysts recently issued reports on ELMD shares. B. Riley started coverage on Electromed in a research note on Thursday, February 20th. They issued a “buy” rating and a $38.00 target price on the stock. StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Institutional Investors Weigh In On Electromed

A number of large investors have recently modified their holdings of ELMD. Arrowstreet Capital Limited Partnership lifted its holdings in Electromed by 261.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock worth $3,386,000 after buying an additional 82,839 shares during the period. Hunter Associates Investment Management LLC raised its position in shares of Electromed by 12.3% in the 3rd quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock worth $2,199,000 after acquiring an additional 11,250 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Electromed by 14.1% in the 4th quarter. Northern Trust Corp now owns 65,350 shares of the company’s stock valued at $1,931,000 after purchasing an additional 8,086 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Electromed during the fourth quarter valued at approximately $1,760,000. Finally, Susquehanna International Group LLP grew its stake in Electromed by 121.8% in the fourth quarter. Susquehanna International Group LLP now owns 56,726 shares of the company’s stock worth $1,676,000 after purchasing an additional 31,148 shares during the period. Institutional investors own 40.82% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.